Table 3.

Subgroup analysis

Subgroup	Outcome measure	Analysis	Donepezil	Placebo	Treatment effect*		P values
			Means (errors)	Means (errors)	Means	(95%CI)
e4 (−)	Psychosis development
	HR for psychosis in 48 weeks	Cox			0.31	(0.11 to 0.86)	0.02
	HR for psychosis in 96 weeks	Cox			0.63	(0.28 to 1.41)	0.26
	Cx in total PPQ	GEE	−0.28 (0.167)	0.60 (0.209)	−0.88	(−1.41 to −0.36)	0.001
	Sleepiness
	Cx in ESS	GEE	0.45 (1.93)	1.85 (1.93)	−1.4	(−2.65 to −0.16)	0.027
e4 (+)	Psychosis development
	HR for psychosis in 48 weeks	Cox			0.85	(0.19 to 3.79)	0.84
	HR for psychosis in 96 weeks	Cox			0.86	(0.23 to 3.32)	0.83
	Cx in total PPQ	GEE	0.02 (0.30)	0.20 (0.331)	−0.18	(−1.05 to 0.70)	0.69
	Sleepiness
	Cx in ESS	GEE	1.26 (3.13)	0.51 (3.19)	0.75	(−0.85 to 2.35)	0.36

*Effect size was estimated using GEE (working matrix M-dependent), adjusted for ESS/10, mH-Y (2.5 vs 3–4) and psychosis history.

Cx, changes; ESS, Epworth Sleep Scale; GEE, generalised estimating equation; mH-Y, modified Hoehn-Yahr; PPQ, Parkinson’s Psychosis Questionnaire.